13 Comments
 

Speculating here... but would have to think it’s in part due to the government funding that is flowing into these spaces to try and stop the spread of COVID-19 and ultimately find a cure. I’m assuming whichever company will be able to mass produce a vaccine will probably see a very large monetary benefit, and firms are probably trying to identify which companies to invest in based on this.

Following this to see if someone closer to the space can confirm.

 

COVID-19 is biotech bubble... No biotech analysts take seriously for COVID except for a few star vaccine and antibody players as COVID actually disturbs all the trials and readout planned and, therefore, the money raising events. Biotech has been compressed for its valuation multiple since 2015/2016 and now kinda bounce back, as Americans realize WW people are free ride USA innovation. With a new wave of technology coming from private companies and entering clinic, we have another 3 years of capital market open for biotech IMHOz

 

Covid and drug makers will be the big talk for likely the next year. Banks are hiring in healthcare as a result of this.

Few players recall big pots they have won, strange as it seems, but every player can remember with remarkable accuracy the outstanding tough beats of his career.
 

There are a few factors imo. There’s a lack of supply of those with sciences/medical backgrounds in finance, the sheer number of public biotechs (around 1000 in the US) that can help generating banking revenues or corporate access business, and healthcare generally being a defensive sector with high growth areas like in biotech.

 

Just to add to it, there are specifics to the sector that make it harder to cover than others. The truth is, having a science/medical background really makes it easier to understand the actual products. (as used as an example in another post on here - if you look at Autoimmune as a class, you have JAK inhibitors, Anti-TNFs, T-Cell Inhibitors, Interleukin Inhibitors, PDE-4 Inhibitors, Corticosteroids, and NSAIDs, among other drug types), or how the drug process works from 1st steps to final FDA approval. While folks with any background can learn, the learning curve is a lot shorter for folks with that background.

 

Agree. But immunology still is more to biopharma than biotech. Oncology is the biggest deal and that really require years of knowledge of pre-clinical and clinical data memory to play well in the field...imagine you have to be familiar with all PD1 PDL1 in development. :(

 
Most Helpful

I don't disagree, but I think that using Immunology could be an easily digestible answer explaining the importance of a scince degree of a medical background. If I wanted to get technical here, Imunology has its biotech roots too. Look at Humira and Infliximab. These are biologics and when they were first introduced, they were at the forefront of biotech. Now, these aren't not Oncology products, and required a big understanding of clinical data when they were first launched too. Oncology is too vast a space to use as something that's easily digestible. I mean you have Car-T, PD1/PDL1, VEGF-A, Anti-CD20, etc. all targeting different subsetsof cancer. And in terms of knowledge, it's more about understanding to read and interpret than it is the nuts and bolts of a specific drug's preclinicals.

 

Quaerat inventore qui facere itaque velit facilis explicabo. Et provident cumque sunt eum aliquam. Asperiores eos omnis labore. Aut unde est sunt excepturi ipsam temporibus molestias.

Corporis eligendi et nostrum itaque possimus et vel. Nihil minima et laborum exercitationem tempore quo. Quaerat iusto ut voluptatum doloribus eum tenetur.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
CompBanker's picture
CompBanker
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”